Gotham Therapeutics has secured $ 54 m in series A financing to develop its RNA - modifying protein therapies . The investment was led by Versant Ventures , Forbion and Capital One , with support from Celgene and Alexandria Venture Investments . The company is aiming to develop technologies related to the emerging field of epitranscriptomics , which differs from epigenetics by focusing on transcribing RNA into proteins rather than transcribing DNA into RNA . Photo: Bill Ingalls, via Getty Images It is expected that development of the technology could have a significant impact on the treatment of numerous health problems , including cancers , autoimmune disorders and neurodegenerative diseases .
Gotham Therapeutics has secured $ 54 m in series A financing to develop its RNA - modifying protein therapies . The investment was led by Versant Ventures , Forbion and Capital One , with support from Celgene and Alexandria Venture Investments . The company is aiming to develop technologies related to the emerging field of epitranscriptomics , which differs from epigenetics by focusing on transcribing RNA into proteins rather than transcribing DNA into RNA . It is expected that development of the technology could have a significant impact on the treatment of numerous health problems , including cancers , autoimmune disorders and neurodegenerative diseases .